Jennifer Berkeley
Neurology · Baltimore, MDNPI 1992858633
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $90,735 of the $105,654 with a category attached, or 85.9%. UCB, Inc. accounts for 65.3% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2022 at $30,124 and has fallen 89.4% since, to $3,206 in 2025. Among neurology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 235 payments — averaging $449.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$69K
- AstraZeneca$28K
- Portola Pharmaceuticals, LLC$6K
- Janssen Research & Development, LLC$1K
- Penumbra, Inc.$430
- Janssen Scientific Affairs, LLC$179
- plus $744 from 10 others
Across 33 payments — averaging $7416.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$166K
- E.r. Squibb & Sons, L.L.C.$35K
- Immedica Pharma US, Inc.$25K
- Biogen$19K
What the payments were for
- Consulting fees$1,4701%
- Speaking & faculty fees$90,73586%
- Travel & lodging$8,0948%
- Food & beverage$5,3565%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 141 | $68,988 |
| AstraZeneca(2 entities) | 52 | $28,235 |
| Portola Pharmaceuticals, LLC | 9 | $5,908 |
| Janssen Research & Development, LLC | 9 | $1,170 |
| Penumbra, Inc. | 2 | $430 |
| Janssen Scientific Affairs, LLC | 2 | $179 |
| AbbVie | 8 | $176 |
| SK Life Science, Inc. | 1 | $125 |
| Immedica Pharma US, Inc. | 1 | $107 |
| Genentech USA, Inc. | 1 | $106 |
| Amgen | 1 | $79 |
| Chiesi USA, Inc. | 4 | $75 |
| Greenwich Biosciences, Inc. | 1 | $35 |
| Neurocrine Biosciences, Inc. | 1 | $17 |
| Integra Lifesciences Corporation | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$105,654 in reported general payments places this provider in the 95th percentile of 442 neurology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Baltimore
- Michael PolydefkisBaltimore$371K
- Shiv SaidhaBaltimore$298K
- Santiago Mazuera MesiaBaltimore$258K
- Thomas CrawfordBaltimore$215K
- Scott NewsomeBaltimore$203K
- Perry ForemanBaltimore$194K
- Samuel MillerBaltimore$179K
- Ted DawsonBaltimore$170K
- Charlene GamaldoBaltimore$131K
- Kathryn WagnerBaltimore$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.